當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院2區(qū) JCRQ1 期刊介紹(非官網(wǎng))

InflammopharmacologySCIE

國際簡稱：INFLAMMOPHARMACOLOGY 參考譯名：炎癥藥理學(xué)

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：0925-4692; E-ISSN：1568-5608; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：NETHERLANDS; 出版商：Springer International Publishing; 出版語言：English; 出版周期：6 issues per year; 出版年份：1991; 研究方向：IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

評價信息：: 影響因子：4.6; H-index：45; CiteScore指數(shù)：8; SJR指數(shù)：0.952; SNIP指數(shù)：1.006

發(fā)文數(shù)據(jù)：: Gold OA文章占比：20.93%; 研究類文章占比：65.78%; 年發(fā)文量：263; 自引率：0.0344...; 開源占比：0.128; 出版撤稿占比：0; 出版國人文章占比：0.15; OA被引用占比：0.0576...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Inflammopharmacology期刊介紹

Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:

-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states

-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs

-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents

-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain

-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs

-Muscle-immune interactions during inflammation [...]

期刊簡介Inflammopharmacology期刊介紹

《Inflammopharmacology》自1991出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個領(lǐng)域的原創(chuàng)研究提供一個展示平臺，以促進醫(yī)學(xué)領(lǐng)域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學(xué)領(lǐng)域的最新進展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關(guān)注點：

預(yù)計審稿時間：
國際TOP期刊
醫(yī)學(xué)
TOXICOLOGY
SCIE
中科院2區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Inflammopharmacology Cite Score數(shù)據(jù)

CiteScore：8
SJR：0.952
SNIP：1.006

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q1	37 / 272	86%
大類：Medicine 小類：Pharmacology	Q1	70 / 313	77%
大類：Medicine 小類：Immunology	Q2	80 / 236	66%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Inflammopharmacology 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	TOXICOLOGY 毒理學(xué) IMMUNOLOGY 免疫學(xué)	1區(qū) 3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運用科學(xué)計量學(xué)方法對國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構(gòu)的管理人員、科研工作者提供了一份評價國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機構(gòu)的廣泛認可。

中科院分區(qū)表 將所有期刊按照一定指標劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領(lǐng)域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Inflammopharmacology JCR分區(qū)

2023-2024 年最新版

按JIF指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q2	56 / 181	69.3%
學(xué)科：TOXICOLOGY	SCIE	Q1	17 / 106	84.4%

按JCI指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q1	37 / 181	79.83%
學(xué)科：TOXICOLOGY	SCIE	Q1	17 / 106	84.43%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學(xué)術(shù)文獻質(zhì)量進行評估。不同學(xué)科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
CHINA MAINLAND79
India76
Brazil60
Iran39
USA23
Pakistan22
Australia20
Egypt18
Saudi Arabia16
England13

本刊中國學(xué)者近年發(fā)表論文

1、Diosmetin alleviates acute lung injury caused by lipopolysaccharide by targeting barrier function
Author: Xia, Jiying; Li, Junhong; Deng, Mengsheng; Yin, Fei; Liu, Jianhui; Wang, Jianmin

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01228-7
2、Phytochemicals as potential target on thioredoxin-interacting protein (TXNIP) for the treatment of cardiovascular diseases
Author: Zhou, Peng; Ma, Yao-yao; Zhao, Xiao-ni; Hua, Fang

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-022-01130-8
3、Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury
Author: Liu, Yuanshui; Yang, Hang; Zhu, Fei; Ouyang, Yanhong; Pan, Pinhua

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01199-9
4、Adalimumab combined with erythropoietin improves recovery from spinal cord injury by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis
Author: Liu, Yanming; Zhang, Feiyue; Sun, Qi; Liang, Lichao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 887-897. DOI: 10.1007/s10787-022-01090-z
5、Suprabasin-derived polypeptides: SBSN(50-63) induces inflammatory response via TLR4-mediated mast cell activation
Author: Zhou, Tong; Du, Xueshan; Zhang, Lei; Zheng, Yi; Jia, Tao; Song, Xiangjin; Che, Delu; Geng, Songmei

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01137-9
6、Synovial mesenchymal stem cell-derived exosomal microRNA-320c facilitates cartilage damage repair by targeting ADAM19-dependent Wnt signalling in osteoarthritis rats
Author: Kong, Ruina; Zhang, Ju; Ji, Lianmei; Yu, Yiyi; Gao, Jie; Zhao, Dongbao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 915-926. DOI: 10.1007/s10787-023-01142-y
7、A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis
Author: Guo, Haohao; Wang, Ziyang; Ma, Runsheng; Chen, Xin; Li, Hongqiang; Tang, Yifeng; Du, Gongbo; Zhang, Yifei; Yin, Detao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 745-754. DOI: 10.1007/s10787-023-01148-6
8、Daidzein attenuated paclitaxel-induced neuropathic pain via the down-regulation of TRPV1/P2Y and up-regulation of Nrf2/HO-1 signaling
Author: Zafar, Sana; Luo, Yong; Zhang, Li; Li, Chang Hu; Khan, Adnan; Khan, Muhammad Ibrar; Shah, Kifayatullah; Seo, Eun Kyoung; Wang, Feng; Khan, Salman

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01225-w